Theravance Biopharma
TBPH
131 hedge funds and large institutions have $401M invested in Theravance Biopharma in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 36 increasing their positions, 48 reducing their positions, and 18 closing their positions.
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
2% more funds holding
Funds holding: 128 → 131 (+3)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.54% less ownership
Funds ownership: 91.29% → 90.75% (-0.54%)
5% less capital invested
Capital invested by funds: $422M → $401M (-$21.5M)
25% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 48
63% less call options, than puts
Call options by funds: $6K | Put options by funds: $16K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$2.26M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.06M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.62M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.15M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$1.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.57M |
| 2 |
BlackRock
New York
|
-$2.43M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.45M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$1.41M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.12M |
TBPH Hedge Fund Activity: Q1 2025 in Review
131 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2025, worth a combined $401M — down 5.1% from $422M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TBPH positions and 18 closed out — a net gain of 4 holders — while 36 added to existing stakes and 48 trimmed.
The largest buyer was UBS Group, adding an estimated $2.26M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $2.57M.
- 131 institutional investors held Theravance Biopharma (TBPH) as of Q1 2025, up from 128 in Q4 2024.
- Funds reported $401M of Theravance Biopharma stock for Q1 2025, down 5.1% quarter-over-quarter.
- 22 funds opened new Theravance Biopharma positions in Q1 2025 and 18 closed out, a net change of +4 holders.
- The largest Theravance Biopharma buyer in Q1 2025 was UBS Group, an estimated $2.26M added.
- The largest Theravance Biopharma seller in Q1 2025 was Jacobs Levy Equity Management, an estimated $2.57M sold.
Based on aggregated 13F filings for Q1 2025.